{"id":43450,"date":"2023-12-18T12:12:07","date_gmt":"2023-12-18T17:12:07","guid":{"rendered":"https:\/\/d56fg8tfg.fitnews.club\/finance\/statement-regarding-illuminas-decision-to-divest-grail\/"},"modified":"2023-12-18T12:12:07","modified_gmt":"2023-12-18T17:12:07","slug":"statement-regarding-illuminas-decision-to-divest-grail","status":"publish","type":"post","link":"https:\/\/d56fg8tfg.fitnews.club\/finance\/statement-regarding-illuminas-decision-to-divest-grail\/","title":{"rendered":"Statement Regarding Illumina\u2019s Decision to Divest Grail"},"content":{"rendered":"
Illumina, Inc. announced it would divest Grail, Inc. following a U.S. Court of Appeals for the Fifth Circuit decision that supported the Federal Trade Commission\u2019s determination that the acquisition threatened competition in the market for cancer detection tests. <\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n Federal Trade Commission Bureau of Competition Director Henry Liu issued the following statement: <\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n \u201cThis is a major win for the FTC as it works to protect competition in health care.\u00a0 Illumina\u2019s decision to unwind its acquisition of Grail ensures the market for cancer detection tests remains competitive and delivers a choice of high-quality tests for patients and physicians, ultimately saving lives. <\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n The Fifth Circuit\u2019s unanimous ruling in this case recognizes how vertical deals can threaten competition and provides a clear roadmap for future cases. The ruling is also a victory for patients who need affordable, high-quality quality cancer detection tests. I applaud FTC staff for their dedication to this case and effort to ensure this critical health care market remains competitive.\u201d <\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n The FTC <\/span><\/span><\/span>challenged<\/span><\/span><\/span><\/a> Illumina\u2019s acquisition of Grail in March 2021 alleging the deal would diminish innovation in the U.S. market for multi-cancer early detection (MCED) tests while increasing prices and decreasing choice and quality of tests. <\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n